Printer Friendly

ALPHA-BETA TECHNOLOGY, INC. REPORTS 1993 FIRST QUARTER RESULTS

 WORCESTER, Mass., May 4 /PRNewswire/ -- Alpha-Beta Technology, Inc. (NASDAQ: ABTI) reported financial results today for the first quarter ended March 31, 1993. For the three-month period, there was a net loss of $3,008,597, or $.33 per share, on revenues of $211,786 and expenses of $3,220,383. The similar quarter for 1992 showed a net loss of $1,305,954, or $.19 per share, on revenues of $98,578 and expenses of $1,404,532.
 "The results reflect our expanding investment in the clinical development of Betafectin(tm) for the prevention and treatment of infection, as well as the development of our other carbohydrate-based health care products," said Dr. Spiros Jamas, president and CEO of Alpha-Beta. "During the quarter we completed our initial Phase II study of Betafectin and began additional clinical trials. Encouraging preliminary results of the Phase II trial, in patients undergoing major chest or abdominal surgery, were presented in January at the International Congress of Biological Response Modifiers.
 "In addition, in February the Rhode Island Post Authority closed on $30 million in taxable revenue bonds for the construction of our Betafectin manufacturing facility. Construction began on the facility, which is located in Smithfield, R.I. The bond financing allows us to preserve equity capital for the development of Betafectin; for Cholestran(tm), our cholesterol-lowering agent; and Fibercel(tm), our dietary fiber supplement and fat substitute."
 Alpha-Beta Technology, Inc. is developing patentable carbohydrate- based products for the health care industry through the application of carbohydrate engineering. The company's major products in development include Betafectin for the treatment and prevention of infections; Cholestran for the treatment and prevention of cardiovascular disease; and Fibercel, a fat substitute. Alpha-Beta's headquarters, laboratory and pilot production facilities are located in Worcester, Mass.
 ALPHA-BETA TECHNOLOGY, INC. AND SUBSIDIARY
 Condensed Consolidated Statement of Operations
 (Unaudited)
 Three Months Ended
 March 31
 1993 1992
 Revenues:
 Product sales $4,335 $7,963
 Interest income 204,625 90,615
 Other income 2,826 0
 Total revenues 211,786 98,578
 Expenses:
 Research and
 development 2,286,893 752,840
 General and
 administrative 902,045 619,207
 Interest expense 31,445 32,485
 Total expenses 3,220,383 1,404,532
 Net loss $(3,008,597) $(1,305,954)
 Loss per share (33 cents) (19 cents)
 Shares used in
 calculation of
 net loss per
 share 9,080,032 7,045,527
 SELECTED CONSOLIDATED BALANCE SHEET DATA
 March 31 December 31
 1993 1992
 (Unaudited)
 Cash, cash
 equivalents,
 & short-term
 investments $14,091,673 $23,810,781
 Other current assets 371,460 371,559
 Total current assets 14,463,133 24,182,340
 Long-term investments 1,497,854 997,648
 Property and equipment,
 net 5,775,163 3,204,947
 Other assets, net 31,426,447 515,852
 Total assets $53,162,597 $28,900,787
 Current liabilities $1,849,272 $2,207,459
 Non-current liabilities 27,320,753 543,042
 Stockholders' equity 23,992,572 26,150,286
 Total liabilities &
 stockholders' equity $53,162,597 $28,900,787
 -0- 5/4/93
 /CONTACT: Spiros Jamas, Sc.D., president and CEO of Alpha-Beta Technology, Inc., 508-798-6900; or Robert Gottlieb, senior vice president of Feinstein Partners Inc., 617-577-8110, for Alpha-Beta Technology/
 (ABTI)


CO: Alpha-Beta Technology, Inc. ST: Massachusetts IN: MTC SU: ERN

DD -- NE001 -- 4149 05/04/93 08:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1993
Words:550
Previous Article:U.S. DRUG TESTING RECEIVES FDA MARKETING APPROVAL
Next Article:MCI SIGNS AGREEMENT WITH FFMC AND GUARDIAN LIFE INSURANCE CO. FOR TELECOM SERVICES VALUED AT $19.6 MILLION
Topics:


Related Articles
RHODE ISLAND PORT AUTHORITY PRICES $30 MILLION TAXABLE REVENUE BONDS TO FINANCE ALPHA-BETA TECHNOLOGY MANUFACTURING FACILITY
ALPHA-BETA TECHNOLOGY, INC. REPORTS YEAR-END FINANCIAL RESULTS
ALPHA-BETA TECHNOLOGY, INC. REPORTS 1993 SECOND QUARTER RESULTS
ALPHA-BETA TECHNOLOGY, INC. REPORTS 1993 THIRD QUARTER RESULTS
ALPHA-BETA TECHNOLOGY, INC. REPORTS FOURTH QUARTER, YEAR-END FINANCIAL RESULTS
ALPHA-BETA TECHNOLOGY ISSUES STATEMENT TO CORRECT ERROR IN DATABASE MONITORING SERVICES
BIOGEN REPORTS FIRST QUARTER EARNINGS OF $0.31 PER SHARE
ALPHA-BETA TECHNOLOGY, INC. REPORTS 1994 FIRST QUARTER RESULTS
ALPHA-BETA TECHNOLOGY, INC. REPORTS 1994 THIRD QUARTER RESULTS
ALPHA-BETA TECHNOLOGY, INC. REPORTS FOURTH QUARTER 1994 YEAR-END FINANCIAL RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters